LMDX

LumiraDx Limited Common Shares

LMDX

Market cap $5.11M

Delisted

LMDX was delisted on the 8th of January, 2024.

Back to rankings

About: LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.

Employees: 1,210

Healthcare Drug Manufacturers - General

Financial journalist opinion

Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform

PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. “We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and.

Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform

Why Is LumiraDx (LMDX) Stock Down 13% Today?

LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards.

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

Roche to buy part of LumiraDx diagnostics platform for $295 million

Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche.

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

Best Penny Stocks Today? 3 To Watch Under $4 Now

Penny stocks can offer traders massive profits through their sheer price volatility. With prices below $5 per share, these tiny companies allow you to snap up many shares.

Penny Stocks To Buy? 4 Under $5 To Watch Right Now

When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.

See News Rankings

Charts implemented using Lightweight Charts™